Ayush Adhikari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ayush Adhikari has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Manoj Khadka
Nepalese Army Institute of Health Sciences
2 shared publications - Pravash Budhathoki
BronxCare Health System, Bronx, NY, USA
2 shared publications - Saurab Karki
Military Hospital, Itahari
2 shared publications - Shekhar Gurung
Shivanagar Primary Health Care Center, Chitwan, Nepal
2 shared publications Amar N. Shrestha
Department of Pathology, Shree Birendra Hospital, Chhauni, Nepal
1 shared publication- Anjala Khadka
Department of Public Health, College of Health and Human Services, University of North Carolina at Charlotte, Charlotte, NC, United States
1 shared publication
Latest Publications
- Open Access
- 30 January 2026
- Published by Wiley in Case Reports in Anesthesiology
- Vol. 2026 (1)
A Successful Anesthesia Management of Intraoperative Cardiac Arrest Secondary to Pneumothorax During Laparoscopy Nephrectomy: A Case Report
Intraoperative cardiac arrest is a rare but life‐threatening condition. Since the patient is under continuous anesthesia monitoring, it is generally rapidly recognized by anesthesiologists. We present a case of a 35‐year‐old female who had an intraoperative collapse during laparoscopy nephrectomy. Shortly after completion of the laparoscopic nephrectomy and prior to extubation, the patient developed sudden cardiovascular collapse and cardiac arrest caused by an unrecognized tension pneumothorax. Cardiopulmonary resuscitation (CPR) was performed for nearly 15 min, and the patient had a return of spontaneous circulation (ROSC). The patient was managed as per Basic Life Support (BLS) and Advanced Cardiac Life Support (ACLS) protocol and was discharged on the 10 th day of admission without any sequelae. To prevent perioperative catastrophic events, the American Society of Anesthesiologists (ASA) Standard II monitoring should be performed; anesthesiologists should be vigilant with a high index of suspicion of such life‐threatening conditions, provide appropriate and timely care, and follow standard management protocol.
- 30 January 2026
- Published by Wiley in Case Reports in Anesthesiology
- Vol. 2026 (1)
Open AccessA Successful Anesthesia Management of Intraoperative Cardiac Arrest Secondary to Pneumothorax During Laparoscopy Nephrectomy: A Case Report
Intraoperative cardiac arrest is a rare but life‐threatening condition. Since the patient is under continuous anesthesia monitoring, it is generally rapidly recognized by anesthesiologists. We present a case of a 35‐year‐old female who had an intraoperative collapse during laparoscopy nephrectomy. Shortly after completion of the laparoscopic nephrectomy and prior to extubation, the patient developed sudden cardiovascular collapse and cardiac arrest caused by an unrecognized tension pneumothorax. Cardiopulmonary resuscitation (CPR) was performed for nearly 15 min, and the patient had a return of spontaneous circulation (ROSC). The patient was managed as per Basic Life Support (BLS) and Advanced Cardiac Life Support (ACLS) protocol and was discharged on the 10 th day of admission without any sequelae. To prevent perioperative catastrophic events, the American Society of Anesthesiologists (ASA) Standard II monitoring should be performed; anesthesiologists should be vigilant with a high index of suspicion of such life‐threatening conditions, provide appropriate and timely care, and follow standard management protocol.
- Open Access
- 15 January 2024
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86 (3) , 1329-1334
Prevalence and clinical characteristics of hyperuricemia among patients with chronic kidney disease under haemodialysis in a tertiary care center: a cross-sectional study
Background: Hyperuricemia is common in chronic kidney disease patients. This study aimed to investigate the prevalence and clinical characteristics of hyperuricemia in patients with chronic kidney disease undergoing haemodialysis. Materials and methods: This cross-sectional study was conducted among 104 patients with chronic kidney disease who visited the haemodialysis unit of a tertiary centre hospital from 11 September 2022, to 11 November 2022. A convenience sampling technique was used. The data were collected using a proforma form, entered into, and analyzed using the Statistical Package for Social Sciences version 21. Results: The mean age group of the study participants was 54.02 ± 14.03 years, and around two-thirds were male (n=70, 67.3%). Almost half of the participants (50, 48.07%) had hyperuricemia with a mean uric acid level of 6.76 ± 2.62 mg/dl. The majority of the participants had associated hypertension (n=100, 96.2%). More than three-fourths of the respondents (83, 79.8%) had haemoglobin levels below the target range. Conclusion: Nearly half of the study participants had hyperuricemia.
- 15 January 2024
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86 (3) , 1329-1334
Open AccessPrevalence and clinical characteristics of hyperuricemia among patients with chronic kidney disease under haemodialysis in a tertiary care center: a cross-sectional study
Background: Hyperuricemia is common in chronic kidney disease patients. This study aimed to investigate the prevalence and clinical characteristics of hyperuricemia in patients with chronic kidney disease undergoing haemodialysis. Materials and methods: This cross-sectional study was conducted among 104 patients with chronic kidney disease who visited the haemodialysis unit of a tertiary centre hospital from 11 September 2022, to 11 November 2022. A convenience sampling technique was used. The data were collected using a proforma form, entered into, and analyzed using the Statistical Package for Social Sciences version 21. Results: The mean age group of the study participants was 54.02 ± 14.03 years, and around two-thirds were male (n=70, 67.3%). Almost half of the participants (50, 48.07%) had hyperuricemia with a mean uric acid level of 6.76 ± 2.62 mg/dl. The majority of the participants had associated hypertension (n=100, 96.2%). More than three-fourths of the respondents (83, 79.8%) had haemoglobin levels below the target range. Conclusion: Nearly half of the study participants had hyperuricemia.
- Open Access
- 23 November 2023
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86 (1) , 382-391
Knowledge and practice regarding cancer screening in Nepal: a systematic review and meta-analysis
Background: Cancer screening utilization can aid in the early diagnosis and treatment of cancer. However, the current scenario of the knowledge and practice regarding cancer screening remains unclear as the authors do not have sufficient studies. Hence, the authors conducted this systematic review and meta-analysis to assess the situation of cancer screening utilization and knowledge. Methods: A systematic literature review was conducted to identify all studies on knowledge and practice regarding cancer screening in the Nepalese population. Data extraction and analysis were done with SPSS and CMA-3. Results: The authors identified a total of 5238 studies after database searching, and 19 studies were included in a narrative synthesis. Lack of awareness and knowledge was the major barrier in cervical, breast, and testicular cancer screening. In cervical cancer screening, the most common reason for screening was the advice of health personnel in 85% of respondents, and the barrier was lack of awareness in 49.33% of participants. Conclusion: The knowledge and practice of cancer screening is lacking in Nepal, as shown by our review. More educational and awareness programs, easy access to screening services, and elimination of sociocultural barriers are necessary to increase the utilization of screening services.
- 23 November 2023
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86 (1) , 382-391
Open AccessKnowledge and practice regarding cancer screening in Nepal: a systematic review and meta-analysis
Background: Cancer screening utilization can aid in the early diagnosis and treatment of cancer. However, the current scenario of the knowledge and practice regarding cancer screening remains unclear as the authors do not have sufficient studies. Hence, the authors conducted this systematic review and meta-analysis to assess the situation of cancer screening utilization and knowledge. Methods: A systematic literature review was conducted to identify all studies on knowledge and practice regarding cancer screening in the Nepalese population. Data extraction and analysis were done with SPSS and CMA-3. Results: The authors identified a total of 5238 studies after database searching, and 19 studies were included in a narrative synthesis. Lack of awareness and knowledge was the major barrier in cervical, breast, and testicular cancer screening. In cervical cancer screening, the most common reason for screening was the advice of health personnel in 85% of respondents, and the barrier was lack of awareness in 49.33% of participants. Conclusion: The knowledge and practice of cancer screening is lacking in Nepal, as shown by our review. More educational and awareness programs, easy access to screening services, and elimination of sociocultural barriers are necessary to increase the utilization of screening services.
- Open Access
- 3 May 2023
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 85 (6) , 3026-3030
Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes syndrome: a case report from Nepal
Introduction and importance: Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like syndrome (MELAS) is a rare neurodegenerative inherited disorder that is characterized by stroke-like episodes, seizures, endocrine, and multiple system involvement. It is important to consider it as a differential diagnosis in a young patient with stroke-like episodes as it is progressive and has multiple complications. Case presentation: A 28-year-old male presented with slurring of speech and drowsiness for 7 h. He was a diagnosed case of type 2 diabetes mellitus, Wolf-Parkinson-White syndrome, and bilateral hearing loss. Clinical findings and investigations: The patient had expressive aphasia with impaired fluency, repetition, and naming. After being discharged, he represented with loss of consciousness and involuntary movements of the whole body. MRI and MRS showed extension of hyperintense lesions to parieto-occipital regions from temporal regions not limited by vascular territories. MELAS was considered, which was confirmed by molecular genetic analysis. Coenzyme Q10 was used for MELAS. Insulin, Linagliptin, and levetiracetam were used for diabetes and seizures. Regular follow-up was advised to the patient. MELAS is an important syndrome to consider in any young patient presenting with unexplained stroke disorders. A high index of suspicion is needed in an appropriate clinical setting to avoid misdiagnosis.
- 3 May 2023
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 85 (6) , 3026-3030
Open AccessMitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes syndrome: a case report from Nepal
Introduction and importance: Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like syndrome (MELAS) is a rare neurodegenerative inherited disorder that is characterized by stroke-like episodes, seizures, endocrine, and multiple system involvement. It is important to consider it as a differential diagnosis in a young patient with stroke-like episodes as it is progressive and has multiple complications. Case presentation: A 28-year-old male presented with slurring of speech and drowsiness for 7 h. He was a diagnosed case of type 2 diabetes mellitus, Wolf-Parkinson-White syndrome, and bilateral hearing loss. Clinical findings and investigations: The patient had expressive aphasia with impaired fluency, repetition, and naming. After being discharged, he represented with loss of consciousness and involuntary movements of the whole body. MRI and MRS showed extension of hyperintense lesions to parieto-occipital regions from temporal regions not limited by vascular territories. MELAS was considered, which was confirmed by molecular genetic analysis. Coenzyme Q10 was used for MELAS. Insulin, Linagliptin, and levetiracetam were used for diabetes and seizures. Regular follow-up was advised to the patient. MELAS is an important syndrome to consider in any young patient presenting with unexplained stroke disorders. A high index of suspicion is needed in an appropriate clinical setting to avoid misdiagnosis.
- Open Access
- 1 February 2023
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 85 (2) , 257-260
Chronic myelomonocytic leukemia in a 72-year-old male from Nepal: A case report
Introduction: Chronic myelomonocytic leukemia (CMML) is a rare disease of clonal hematopoietic stem cells with an inherent risk of leukemic transformation, seen in an elderly male. Case Presentation: Herein, the authors report a case of CMML in a 72-year-old male who presented with fever and abdominal pain for 2 days with a history of easy fatigability. Examination revealed pallor and palpable supraclavicular nodes. Investigations showed leukocytosis with a monocyte count of 22% of white blood cell count, 17% blast cells in bone marrow aspiration, increased blast/promonocytes, and positive markers in immunophenotyping. The patient is planned for injection of azacitidine, 7 days cycle for a total of six cycles. Clinical Discussion: CMML is classified as overlapping myelodysplastic/myeloproliferative neoplasms. It can be diagnosed based on a peripheral blood smear, bone marrow aspiration and biopsy, chromosomal analysis, and genetic tests. The commonly used treatment options are hypomethylating agents like azacitidine and decitabine, allogeneic hematopoietic stem cell transplant, and cytoreductive agents like hydroxyurea. Conclusion: Despite various treatment options, the treatment is still unsatisfactory, demanding standard management strategies.
- 1 February 2023
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 85 (2) , 257-260
Open AccessChronic myelomonocytic leukemia in a 72-year-old male from Nepal: A case report
Introduction: Chronic myelomonocytic leukemia (CMML) is a rare disease of clonal hematopoietic stem cells with an inherent risk of leukemic transformation, seen in an elderly male. Case Presentation: Herein, the authors report a case of CMML in a 72-year-old male who presented with fever and abdominal pain for 2 days with a history of easy fatigability. Examination revealed pallor and palpable supraclavicular nodes. Investigations showed leukocytosis with a monocyte count of 22% of white blood cell count, 17% blast cells in bone marrow aspiration, increased blast/promonocytes, and positive markers in immunophenotyping. The patient is planned for injection of azacitidine, 7 days cycle for a total of six cycles. Clinical Discussion: CMML is classified as overlapping myelodysplastic/myeloproliferative neoplasms. It can be diagnosed based on a peripheral blood smear, bone marrow aspiration and biopsy, chromosomal analysis, and genetic tests. The commonly used treatment options are hypomethylating agents like azacitidine and decitabine, allogeneic hematopoietic stem cell transplant, and cytoreductive agents like hydroxyurea. Conclusion: Despite various treatment options, the treatment is still unsatisfactory, demanding standard management strategies.
- Open Access
- 23 December 2021
- Published by Springer Nature in Cureus
- Vol. 13 (12) , e20632
Efficacy and Safety of Andexanet Alfa for Bleeding Caused by Factor Xa Inhibitors: A Systematic Review and Meta-Analysis
Direct oral anticoagulants (DOAC) including factor Xa inhibitors are associated with bleeding events which can lead to severe morbidity and mortality. Reversal agents like andexanet alfa (AA) and 4F-PCC (Four-factor prothrombin concentrate complex) are available for treating bleeding that occurs with DOAC therapy but a comparison on their efficacy is lacking. In this study, we analyzed the efficacy and safety of patients treated with andexanet alfa for bleeding events from DOAC. Databases were searched for relevant studies where AA was used to determine efficacy and safety in bleeding patients who were on factor Xa inhibitors. Published papers were screened independently by two authors. RevMan 5.4 (The Cochrane Collaboration, 2020) was used for data synthesis. Odds ratio (OR) and mean difference (MD) was used to estimate the outcome with a 95% confidence interval (CI). Among 1245 studies were identified after a thorough database search and three studies were included for analysis. AA resulted in lower odds of mortality compared to 4F- PCC (OR, 0.37; 95% CI, 0.20-0.71) among patients with intracerebral hemorrhage. There was no difference in thrombotic events between patients receiving AA and 4F-PCC (OR, 2.40; 95% CI, 0.36-15.84). No differences in length of hospital stay and intensive care unit (ICU) stay were seen between patients receiving AA and 4F-PCC. In conclusion, andexanet alfa reduced in-hospital mortality in patients who had bleeding due to factor Xa inhibitors compared to 4F-PCC. However, there were no differences in thrombotic events, length of ICU, and hospital stay between patients treated with AA and 4F-PCC.
- 23 December 2021
- Published by Springer Nature in Cureus
- Vol. 13 (12) , e20632
Open AccessEfficacy and Safety of Andexanet Alfa for Bleeding Caused by Factor Xa Inhibitors: A Systematic Review and Meta-Analysis
Direct oral anticoagulants (DOAC) including factor Xa inhibitors are associated with bleeding events which can lead to severe morbidity and mortality. Reversal agents like andexanet alfa (AA) and 4F-PCC (Four-factor prothrombin concentrate complex) are available for treating bleeding that occurs with DOAC therapy but a comparison on their efficacy is lacking. In this study, we analyzed the efficacy and safety of patients treated with andexanet alfa for bleeding events from DOAC. Databases were searched for relevant studies where AA was used to determine efficacy and safety in bleeding patients who were on factor Xa inhibitors. Published papers were screened independently by two authors. RevMan 5.4 (The Cochrane Collaboration, 2020) was used for data synthesis. Odds ratio (OR) and mean difference (MD) was used to estimate the outcome with a 95% confidence interval (CI). Among 1245 studies were identified after a thorough database search and three studies were included for analysis. AA resulted in lower odds of mortality compared to 4F- PCC (OR, 0.37; 95% CI, 0.20-0.71) among patients with intracerebral hemorrhage. There was no difference in thrombotic events between patients receiving AA and 4F-PCC (OR, 2.40; 95% CI, 0.36-15.84). No differences in length of hospital stay and intensive care unit (ICU) stay were seen between patients receiving AA and 4F-PCC. In conclusion, andexanet alfa reduced in-hospital mortality in patients who had bleeding due to factor Xa inhibitors compared to 4F-PCC. However, there were no differences in thrombotic events, length of ICU, and hospital stay between patients treated with AA and 4F-PCC.